TD Private Client Wealth’s Biohaven BHVN Stock Holding History

TD Private Client Wealth’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-42	Closed	-$630	–	1646
2025 Q3	$630	Buy	+42	New	+$611	﹤0.01%	1420

Other funds holding BHVN

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RPSM

Royalty Pharma Sub-Manager New York $242M AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TD Private Client Wealth's BHVN Position: Q4 2025 in Review

TD Private Client Wealth sold out of Biohaven (BHVN) in Q4 2025, closing a stake of 42 shares — an estimated $630 sold.

TD Private Client Wealth first reported a position in BHVN in Q3 2025 and held it in 1 quarter. The position peaked at $630 in Q3 2025. 273 funds tracked by Wall St. Rank hold BHVN as of Q4 2025.

TD Private Client Wealth reported no remaining Biohaven position as of Q4 2025 after selling out during the quarter.
TD Private Client Wealth sold 42 Biohaven shares in Q4 2025, an estimated $630.
TD Private Client Wealth first reported a position in Biohaven in Q3 2025 and held it in 1 quarter.
TD Private Client Wealth's Biohaven position peaked at $630 in Q3 2025.
273 funds tracked by Wall St. Rank held Biohaven as of Q4 2025.

Based on TD Private Client Wealth's 13F filing for Q4 2025, filed 5 Feb 2026.